All In Biotech

Drug Trial Radar · NCT05066698

ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects

A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects

Last checked: Nov 19, 2026Latest source record: Oct 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

8

Actual

Start

Apr 27, 2022

Primary completion

Sep 7, 2022

Study completion Sep 7, 2022

Sponsor

Sponsor type
Industry
Collaborators
IQVIA Biotech
First posted
Oct 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.

Conditions

  • Persistent Corneal Epithelial Defect

Interventions

  • ST266Biological

    Topical ocular application: one drop four times a day for eight weeks

  • 0.67% Sodium Chloride Ophthalmic SolutionOther

    Topical ocular application: one drop four times a day for eight weeks

  • Open-label ST266Biological

    Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical SuccessTime frame: 8 weeks

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Trinity Research Group

    Dothan, Alabama

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Atlantis Eye Care

    Huntington Beach, California

  • UCLA Stein Eye Institute

    Los Angeles, California

  • Stanford

    Palo Alto, California

  • UCLA Doheny Eye Center

    Pasadena, California

  • California Eye Specialists Medical Group

    Pasadena, California

  • Bowden Eye & Associates

    Jacksonville, Florida

  • Shettle Eye Research

    Largo, Florida

  • Millennium Clinical Research, Inc

    Miami, Florida

  • MedEye Associates

    Miami, Florida

  • Cincinnati Eye Institute

    Edgewood, Kentucky

  • University of Maryland Eye Associates

    Baltimore, Maryland

  • Tufts Medical Center

    Boston, Massachusetts

  • Massachusetts Eye and Ear

    Boston, Massachusetts

  • Mercy Clinic Eye Specialists- Ophthalmology

    Springfield, Missouri

  • UNMC Truhlsen Eye Institute

    Omaha, Nebraska

  • UNC Kittner Eye Center

    Chapel Hill, North Carolina

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • OSU Wexner Medical Center

    Columbus, Ohio

  • Ophthalmic Partners, PC

    Bala-Cynwyd, Pennsylvania

  • Vanderbilt Eye Institute

    Nashville, Tennessee

  • Houston Eye Associates

    Houston, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Blanton Eye Institute/Houston Methodist Eye Associates

    Houston, Texas

  • Texas Eye Research Center

    Hurst, Texas

  • R and R Eye Research, LLC

    San Antonio, Texas

  • Piedmont Eye Center

    Lynchburg, Virginia

  • WVU Eye Institute

    Morgantown, West Virginia

  • The Eye Centers of Racine and Kenosha

    Kenosha, Wisconsin

  • University of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.